Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma.

In a multicentre study, 83 patients with advanced and previously uniformly treated multiple myeloma (MM) were randomised between cyclophosphamide (600 mg m-2) and epirubicin (70 mg m-2), administered every 3 weeks for three courses and both associated with prednisone and interferon-alpha2b. Both reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Brugnatelli, S., Riccardi, A., Ucci, G., Mora, O., Barbarano, L., Piva, N., Piccinini, L., Bergonzi, C., De Paoli, A., Di Stasi, M., Rinaldi, E., Trotti, G., Petrini, M., Ascari, E.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074366/
https://www.ncbi.nlm.nih.gov/pubmed/8611382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074366/
https://www.ncbi.nlm.nih.gov/pubmed/8611382

Ejemplares similares